IanRabinowitzMD

Oncology • Albuquerque, NM

Professor, Internal Medicine, University of New Mexico School of Medicine

Join to view full profile

Dr. Rabinowitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rabinowitz's full profile

Already have an account?

Office
UNM Cancer Ctr
1201 Camino de Salud NE
Albuquerque, NM 87131
Phone+1 505-272-4946

Fax+1 505-925-0100

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 1989 - 1992
Vanderbilt University Medical CenterResidency, Internal Medicine, 1986 - 1989
University of the WitwatersrandClass of 1984

Certifications & Licensure

NM State Medical License 1997 - 2025
TN State Medical License 1989 - 1992
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2014

Clinical Trials

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
Completed
Phase 3
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors Start of enrollment: 2004 Apr 01
Completed
Phase 1
Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen Start of enrollment: 2004 Apr 01
Completed
Not Applicable
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec Start of enrollment: 2004 Apr 01
Completed
Phase 2
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma Start of enrollment: 2000 Sep 01
Completed
Phase 2
INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma. Start of enrollment: 2002 Aug 01
Completed
Phase 2
Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer. Start of enrollment: 1999 Feb 01
Terminated
A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes Start of enrollment: 2002 Jun 01
Completed
Phase 3
Dysregulated Tyrosine Kinase Signaling in Leukemia Start of enrollment: 2002 May 01
Terminated
Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer Start of enrollment: 2000 May 01
Completed
Phase 1, Phase 2
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer Start of enrollment: 2008 Sep 01
Terminated
Phase 3
A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) Start of enrollment: 2009 Sep 01
Withdrawn
Phase 2
Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2014 Jul 01
Terminated
Phase 1
Compassionate Use of BYL 719 Alpelisib
No longer available
Join now to see all

Publications & Presentations

PubMed

1 citations
The Equipoise Between the Treatment of Glioblastoma and the Risk of Secondary Acute Myelogenous Leukemia: An Illustrative Case Report.
Moises Harari-Turquie, Krishna Rekha Moturi, Darrell D Horton, Ian Rabinowitz
Journal of Investigative Medicine High Impact Case Reports. 2023-08-19
3 citations
The inflammatory response of human pancreatic cancer samples compared to normal controls.
Kathryn J Brayer, Joshua A Hanson, Shashank Cingam, Cathleen Martinez, Scott A Ness
Plos One. 2023-01-01
9 citations
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an-of-1 clinical trial.
Montaser F Shaheen, Julie Y Tse, Ethan S Sokol, Margaret Masterson, Pranshu Bansal
Elife. 2022-07-05

Press Mentions

Reader Responses: Should a Pregnant Patient with Hemochromatosis Receive Iron?September 1st, 2020
Colorectal Cancer Awareness MonthMarch 19th, 2018

Professional Memberships

American Society of Clinical Oncology - ASCO
Member